Pentylenetetrazol

 ( Antidepressants ) 

Pentylenetetrazol ( PTZ), also known as pentylenetetrazole, pentetrazol (INN), and pentamethylenetetrazol, is a drug formerly used as a circulatory and respiratory stimulant. High doses cause , as discovered by Hungarian-American neurologist and psychiatrist Ladislas J. Meduna in 1934. It has been used in convulsive therapy, and was found to be effective in treating depression, but side effects, such as uncontrolled , were difficult to avoid. In 1939, pentylenetetrazol was replaced by electroconvulsive therapy, which is easier to administer, as the preferred method for inducing seizures in England's mental hospitals. In the US, pentylenetetrazol’s approval by the Food and Drug Administration (FDA) was revoked in 1982. It is used in Italy as a cardio-respiratory stimulant in combination with dihydrocodeine in a cough suppressant drug.

---

Side effects Pentylenetetrazol is anxiogenic and has been known to induce severe anxiety in humans.

(2026). 9783642029110, Springer Berlin Heidelberg. ISBN 9783642029110

---

Mechanism of action The mechanism of pentylenetetrazol is not well understood, and it may have multiple mechanisms of action. In 1984, Squires et al. published a report analyzing pentylenetetrazol and several structurally related convulsant drugs. They found that in vivo convulsant potency was strongly correlated to in vitro affinity to the picrotoxin binding site on the GABA-A receptor complex. Many GABA_A receptor ligands, such as diazepam and phenobarbital, are effective , but pentylenetetrazol presumably has the opposite effect when it binds to the GABA_A receptor.

Several studies have focused on the way pentylenetetrazol influences neuronal ion channels. A 1987 study found that pentylenetetrazol increases calcium influx and sodium influx, both of which depolarize the neuron. Because these effects were antagonized by calcium channel blockers, pentylenetetrazol apparently acts at , and it causes them to lose selectivity and conduct sodium ions, as well.

---

Research Pentylenetetrazol has been used experimentally to study seizure phenomena and to identify pharmaceuticals that may control seizure susceptibility. For instance, researchers can induce status epilepticus in animal models. Pentylenetetrazol is also a prototypical anxiogenic drug and has been extensively used in animal models of anxiety. Pentylenetetrazol produces a reliable discriminative stimulus, which is largely mediated by the GABA_A receptor. Several classes of compounds can modulate the pentylenetetrazol discriminative stimulus, including 5-HT_1A, 5-HT₃, NMDA, glycine, and L-type calcium channel .

Pentylenetetrazol is being studied as a wakefulness-promoting agent in the treatment of idiopathic hypersomnia and narcolepsy.

---

See also

• List of investigational narcolepsy and hypersomnia drugs
• GABA_A receptor negative allosteric modulator
• GABA_A receptor § Ligands

Post Comment